Chikuma Hamada

Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial

Koji Abe, Masashi Aoki, Shoji Tsuji et al. · The Lancet Neurology · 2017 · 900 citations

Neurodegenerative Diseases, Amyotrophic Lateral Sclerosis, Neurological Disorder +6

Cilostazol for prevention of secondary stroke (CSPS 2): an aspirin-controlled, double-blind, randomised non-inferiority trial

Yukito Shinohara, Yasuo Katayama, Shinichiro Uchiyama et al. · The Lancet Neurology · 2010 · 483 citations

Thrombosis, Ischemic Stroke, Cardiovascular Disease +15

Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients

Koji Abe, Yasuto Itoyama, Gen Sobue et al. · Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration · 2014 · 348 citations · Full text

TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trial

Takayuki Yoshino, Nobuyuki Mizunuma, Kentaro Yamazaki et al. · The Lancet Oncology · 2012 · 319 citations

Placebo-controlled Phase 2, Tas-102 Monotherapy, Gastrointestinal Oncology +9

Evidence for association between paraoxonase gene polymorphisms and atherosclerotic diseases

Yasushi Imai, Hiroyuki Morita, Hiroki Kurihara et al. · Atherosclerosis · 2000 · 187 citations

Genetics, Genetic Epidemiology, Human Polymorphism +10